These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
699 related articles for article (PubMed ID: 29038906)
41. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Okere AN; Serra C Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279 [TBL] [Abstract][Full Text] [Related]
42. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
43. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Arca M Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383 [TBL] [Abstract][Full Text] [Related]
44. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. Patel RS; Scopelliti EM; Olugbile O Ann Pharmacother; 2018 Oct; 52(10):1000-1018. PubMed ID: 29667842 [TBL] [Abstract][Full Text] [Related]
46. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations. Krempf M; Hopkins PN; Bruckert E; Lee S; Donahue S Am J Cardiol; 2020 Mar; 125(6):880-886. PubMed ID: 31932084 [TBL] [Abstract][Full Text] [Related]
48. Evolocumab (AMG 145) for primary hypercholesterolemia. Langslet G; Emery M; Wasserman SM Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308 [TBL] [Abstract][Full Text] [Related]
49. Evolocumab: Considerations for the Management of Hyperlipidemia. Wiggins BS; Senfield J; Kassahun H; Lira A; Somaratne R Curr Atheroscler Rep; 2018 Mar; 20(4):17. PubMed ID: 29511875 [TBL] [Abstract][Full Text] [Related]
50. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia. Schmitz J; Gouni-Berthold I Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia. Ascaso JF Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861 [No Abstract] [Full Text] [Related]
52. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886 [TBL] [Abstract][Full Text] [Related]
53. Recent advances in the pharmacological management of hypercholesterolaemia. Ajufo E; Rader DJ Lancet Diabetes Endocrinol; 2016 May; 4(5):436-46. PubMed ID: 27012540 [TBL] [Abstract][Full Text] [Related]
54. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. Tziomalos K Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622 [TBL] [Abstract][Full Text] [Related]
58. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Hooper AJ; Burnett JR Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807 [TBL] [Abstract][Full Text] [Related]
59. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. Ortega Martínez de Victoria E Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604 [No Abstract] [Full Text] [Related]